Cholesterol drug names
Pro Research Analysisby 
Searched over 200M research papers
Cholesterol Drug Names: An Overview
Statins: The Most Common Cholesterol-Lowering Drugs
Statins are the most frequently prescribed cholesterol-lowering drugs. They work by inhibiting the enzyme hydroxyl methyl CoA reductase, which is crucial for cholesterol biosynthesis in the liver. Common statins include atorvastatin, lovastatin, pravastatin, and simvastatin 67. Rosuvastatin, marketed under the brand name Crestor, is currently the most-prescribed statin in the United States, with an estimated 23.7 million prescriptions and refills in the past year .
Emerging Cholesterol-Lowering Therapies
Oligonucleotide Therapeutics
A new class of cholesterol-lowering drugs involves chemically modified small interfering RNA (siRNA) conjugated to trivalent N-acetylgalactosamine. These siRNAs are designed to destroy RNA before protein synthesis, offering a novel approach to reducing cholesterol levels .
Berberine
Berberine (BBR), a compound derived from a Chinese herb, has been identified as a new cholesterol-lowering agent. It works through a unique mechanism distinct from statins by upregulating LDL receptor expression via ERK activation, leading to significant reductions in serum cholesterol and LDL-cholesterol levels .
Generic vs. Brand-Name Drugs
A meta-analysis comparing the efficacy and adverse events of generic versus brand-name cardiovascular drugs, including statins, found no significant differences in outcomes. This supports the clinical equivalence of generic and brand-name cholesterol-lowering medications, reassuring physicians and healthcare organizations about the use of generics .
Fixed-Dose Combination (FDC) Products
The release of the 2013 ACC/AHA cholesterol guidelines has promoted the use of fixed-dose combination products. Vytorin, which combines ezetimibe and simvastatin, is one of the most commonly used FDCs. These combinations are particularly beneficial for high-risk patients, offering increased effectiveness and reduced adverse effects .
Novel Mechanisms and Future Directions
Cholesterol Trafficking Inhibitors
Cepharanthine, an existing drug used for anti-inflammatory and cancer management, has been identified as a cholesterol trafficking inhibitor. It works by binding to the NPC1 protein, increasing lysosomal pH, and inhibiting cholesterol trafficking, which in turn suppresses angiogenesis and tumor growth .
Enzyme Inhibitors
Drugs targeting various stages of the cholesterol biosynthetic pathway, such as squalene synthase inhibitors, are entering clinical development. Additionally, inhibitors of enzymes involved in hepatic very low-density lipoprotein assembly, like microsomal triglyceride transfer protein inhibitors and apolipoprotein B mRNA antisense oligonucleotides, are being evaluated .
Conclusion
The landscape of cholesterol-lowering drugs is diverse, ranging from well-established statins to emerging therapies like siRNA-based drugs and berberine. The equivalence of generic and brand-name drugs further broadens the options available to patients. As research continues, new mechanisms and drug classes promise to enhance the management of cholesterol levels and associated cardiovascular risks.
Sources and full results
Most relevant research papers on this topic